Amsacrine

• 

  Subject Areas on Research

  • A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents. 
  • An antitumor drug-induced topoisomerase cleavage complex blocks a bacteriophage T4 replication fork in vivo. 
  • Analysis of cleavage complexes using reactive inhibitor derivatives. 
  • Bacteriophage T4 DNA topoisomerase is the target of antitumor agent 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) in T4-infected Escherichia coli. 
  • Bacteriophage T4 mutants hypersensitive to an antitumor agent that induces topoisomerase-DNA cleavage complexes. 
  • Bacteriophage T4, a model system for understanding the mechanism of type II topoisomerase inhibitors. 
  • Disruption of a topoisomerase-DNA cleavage complex by a DNA helicase. 
  • Evidence for a common mechanism of action for antitumor and antibacterial agents that inhibit type II DNA topoisomerases. 
  • Hepatic candidiasis: persistent pyrexia in a patient with acute myeloid leukaemia after recovery from consolidation therapy-induced neutropenia. 
  • High-dose amsacrine (AMSA) therapy of relapsed and refractory adult acute nonlymphocytic leukemia. A phase II study. 
  • Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex. 
  • Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial). 
  • Mutational alteration of the breakage/resealing subunit of bacteriophage T4 DNA topoisomerase confers resistance to antitumor agent m-AMSA. 
  • Mutations of the bacteriophage T4 type II DNA topoisomerase that alter sensitivity to antitumor agent 4'-(9-acridinylamino)methanesulfon-m-anisidide and an antibacterial quinolone. 
  • Nucleic acid binding drugs--XIV. The crystal structure of 1-methyl amsacrine hydrochloride; relationships to DNA-binding ability and anti-tumour activity. 
  • Polyploidy induction as a consequence of topoisomerase inhibition. A flow cytometric assessment. 
  • Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. 
  • Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. 
  • Regression supports two mechanisms of fork processing in phage T4. 
  • Repair of topoisomerase-mediated DNA damage in bacteriophage T4. 
  • Role of recombinational repair in sensitivity to an antitumour agent that inhibits bacteriophage T4 type II DNA topoisomerase. 
  • The specificity of topoisomerase-mediated DNA cleavage defines acridine-induced frameshift specificity within a hotspot in bacteriophage T4. 
  • Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial.